Continue to Site

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » PPD Inc.’s Q4 sales and earnings slide

PPD Inc.’s Q4 sales and earnings slide

By

PPD Inc. (NSDQ:PPDI) posted fourth-quarter sales of $357.4 million for the three months ended Dec. 31, 2009, down 1.6 percent compared with $363.1 million during the same period last year. Net income fell 59.8 percent to $19 million, compared with $47.2 million during Q4 2008:

Press Release

PPD Reports Fourth Quarter and Full Year 2009 Financial Results

Highlights:

  • Completed two strategic acquisitions in China
  • Full year 2009 cash flow from operations of $253 million
  • Establishing strategic outsourcing partnerships
  • Planning to spin off compound partnering business by mid-2010

WILMINGTON, N.C. (February 8, 2010) – PPD, Inc. (Nasdaq: PPDI) today reported its financial and operating results for the fourth quarter and full year ended December 31, 2009.

PPD recorded net revenue of $357.4 million for the fourth quarter of 2009, compared to $363.1 million for the fourth quarter of 2008. Fourth quarter 2009 income from operations was $23.9 million, compared to $71.7 million for the same period in 2008. Fourth quarter 2009 diluted earnings per share were $0.16, compared to $0.40 for the same period last year. Fourth quarter 2009 diluted earnings per share included impairments of an intangible asset and equity investments totaling $10.0 million, net of tax, related to the company’s dermatology program within the compound partnering business and the company’s investment portfolio, respectively.

Net revenue for the full year ended December 31, 2009, was $1.42 billion, compared to net revenue of $1.55 billion for the full year 2008. Full year 2009 income from operations was $192.9 million, compared to income from operations of $282.4 million for the same period in 2008. Diluted earnings per share for the full year 2009 were $1.34, compared to diluted earnings per share of $1.56 for the same period last year.

Development

Development segment net revenue for the fourth quarter of 2009 was $328.1 million, compared to $338.7 million for the fourth quarter of 2008. Development segment income from operations for the fourth quarter of 2009 was $49.4 million, compared to $72.6 million for the fourth quarter of 2008.

Full year 2009 development segment net revenue was $1.31 billion, compared to net revenue of $1.42 billion for the full year 2008. Development segment income from operations for the full year 2009 was $223.2 million, compared to income from operations of $272.5 million for the same period in 2008. Full year 2009 income from operations for this segment included restructuring costs of $3.9 million.

Discovery Sciences

Discovery sciences segment net revenue for the fourth quarter of 2009 was $0.5 million, compared to $0.1 million for the fourth quarter of 2008. Discovery sciences segment loss from operations for the fourth quarter of 2009 was $25.5 million, compared to a loss from operations of $0.9 million for the same period in 2008. The loss for the fourth quarter of 2009 was higher than the prior year loss due to the impairment of an intangible asset, an increase in research and development expenditures related to the company’s dermatology business and the upfront costs and research and development expenses related to the two compounds PPD in-licensed from Janssen Pharmaceutica N.V. in the fourth quarter of 2009.

Full year 2009 discovery sciences segment net revenue was $6.3 million, compared to net revenue of $18.4 million for the full year 2008. Full year 2008 discovery sciences segment net revenue included two milestone payments from Takeda Pharmaceutical Company Limited totaling $18.0 million triggered by the U.S. Food and Drug Administration’s acceptance of Takeda’s new drug application, or NDA, for alogliptin in the United States and the submission of its NDA for alogliptin to the Ministry of Health, Labour and Welfare in Japan. Discovery sciences segment loss from operations for the full year 2009 was $30.3 million, compared to income from operations of $9.9 million for the same period in 2008.

As previously disclosed, in April 2009, PPD sold the assets of its wholly owned subsidiary, Piedmont Research Center, LLC. In December 2009, PPD also completed the sale of its wholly owned subsidiary, PPD Biomarker Discovery Sciences, LLC, which owned and operated a biomarker discovery laboratory in Menlo Park, CA. These businesses were part of the company’s discovery sciences segment. Therefore, the company is reporting current and historical financial results for these businesses in discontinued operations.

Other Financial Information

New business authorizations for the fourth quarter of 2009 totaled $465.6 million. Backlog at December 31, 2009, was $3.0 billion. Contract cancellations and adjustments for the quarter were $284.9 million, including three large project cancellations that together represented approximately four percent of year-end backlog.

Days sales outstanding for the full year 2009 were 31.3 days, compared to 42.2 days at December 31, 2008. Cash flow from operations for the fourth quarter of 2009 was $115.9 million. At December 31, 2009, PPD had $642.1 million in cash and investments. The effective tax rate for continuing operations in the fourth quarter of 2009 was approximately 20 percent.

"Although fourth quarter cancellations and adjustments were higher than anticipated, we delivered strong operating cash flow during the quarter and we are continuing to establish new strategic outsourcing partnerships," said David Grange, chief executive officer of PPD. "We remain committed to combining our financial and operational strength with our unrelenting focus on creating efficient solutions for our clients to maximize value for our shareholders."

Fred Eshelman, executive chairman of PPD, added, "PPD made significant progress on several strategic fronts in 2009, as evidenced by acquisitions and investments in emerging markets, expansion in new service areas, and the anticipated spin-off of our compound partnering business. We continue to believe in the fundamentals of the market for CRO services, and we intend to continue to focus on sales execution, operational performance, and building strategic partnerships with clients in the year ahead."

In case you missed it

RSS From Medical Design & Outsourcing

  • 5 keys to Mike Mahoney and Boston Scientific’s success
    Boston Scientific is one of the bright spots as the medical device industry goes through a rough patch. It’s more expensive to run a business, and health provider customers face operational challenges. But while other medtech companies are laying off workers, Boston Scientific is hiring. The interventional medical device giant’s workforce grew 10% over the… […]
  • New Expanded Line Of Sorbothane® Standard Products Available Now
    Sorbothane, Inc. offers an extensive line of over 600 standard Sorbothane parts. Sorbothane Bushings and Washers, shock attenuating Hemispheres, Stud Mounts and Bumpers are included. Sorbothane Sheet Stock is available in a variety of styles, thicknesses and durometers. Download the Sorbothane Standard Products Guide Via the Form Below:   The post New Expanded Line Of […]
  • World’s largest contract chlorine dioxide sterilization chamber opens soon
    Boulder iQ division Boulder Sterilization will open what it said is the world’s largest contract chlorine dioxide (CD) sterilization chamber this summer. The 270-ft² chamber has capacity for two pallets at a time, allowing for batches and products of almost any size, the company said. Boulder, Colorado-based Boulder iQ said the new equipment will make… […]
  • Design firm Delve makes first acquisition under new owner
    Delve announced its acquisition of Boston-based digital innovation and design firm Altr this week. Madison, Wisconsin–based Delve said Altr is its first acquisition under the ownership of private equity firm Trinity Hunt Partners, which purchased Delve in May 2021 and merged it with product design consultancy firm Bresslergroup. “Almost two years ago to the day,… […]
  • 5 critical questions medical device manufacturers must ask potential lab testing partners
    You can learn a lot about a potential medical device testing partner by asking about experience, capacity, testing approaches, communication and pre-submission meetings. By Sandi Schaible, WuXi AppTec Medical Device Testing Selecting a laboratory testing partner can be tricky — it goes well beyond mere technical capabilities. Knowing the right questions to ask when choosing… […]
  • Okay Industries promotes to fill laser technologies manager role
    NEWS RELEASE: Okay Industries promotes Redi Nasto Okay Industries, a contract manufacturer of components and subassemblies for global original equipment manufacturers in the medical device markets, is pleased to announce the promotion of Redi Nasto to laser technologies manager. In his new role, Nasto will lead and manage all aspects of laser technologies and processes,… […]
  • 80-cent device prototype uses smartphone to monitor blood pressure
    University of California San Diego engineers have prototyped an inexpensive device that clips onto a smartphone to monitor a user’s blood pressure. The 3D-printed device uses the smartphone’s camera and flash paired with an algorithm on an app to take systolic and diastolic blood pressure readings. “We’ve created an inexpensive solution to lower the barrier… […]
  • The rundown on dip manufacturing for medical devices
    Dip molding and dip coating each have advantages and drawbacks for medical device manufacturing. By Dan Sanchez, Trelleborg Healthcare & Medical Dip molding and coating involve immersing an object into liquid silicone and either forming or coating a component. These methods can contribute to the success of a medical device project when correctly specified for… […]
  • Going Beyond In The Medical Devices Industry: Advanced Materials With USP Class VI Certification
    By Ronelle Decker, Senior Business Development Manager – Omniseal Solutions™ Life Science High Performance Life Science Material Options & Solutions Omniseal Solutions™ is a leading global engineering company specializing in the design and manufacture of precision sealing and material solutions for critical applications in challenging environments. For over 65 years, they have provided life science… […]
  • They said it at DeviceTalks Boston 2023
    Medical device industry leaders from Boston Scientific, Becton Dickinson, ZimVie, Medtronic, Stryker and more met at DeviceTalks Boston to share lessons learned and their perspectives on industry trends, device design and medtech innovation. Bidding farewell to DeviceTalks Boston 2023, we look back at an exceptional two-day medical device conference teeming with insights from over 100… […]
  • How LivaNova developed a next-generation perfusion system
    Access to technology, integrated systems and data reign supreme in the new era of perfusion. By Marco Dolci, LivaNova  Perfusionists are essential players on a cardiac surgery team, ensuring patients receive critical clinical support to maintain vital functions during a procedure. In short, the breath and heartbeat of patients’ lives rest in the hands of… […]

Copyright © 2023 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy